Old dogs—new tricks: immunoregulatory properties of C3 and C5 cleavage fragments

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 112-126

  Verschoor, Admar ^a   Karsten, Christian M ^a   Broadley, Steven P ^a   Laumonnier, Yves ^a   Köhl, Jörg ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

asthma; complement; Fc receptors; infectious diseases; inflammation; lung

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT IC3B; COMPLEMENT RECEPTOR; DECTIN 1; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 6; LECTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROPERDIN; PROTEIN KINASE B; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ANTIGEN ANTIBODY COMPLEX; BACTERIUM; BASOPHIL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DERMATOPHAGOIDES; EOSINOPHIL; HUMAN; IMMUNE ADHERENCE; IMMUNOMODULATION; IMMUNOREGULATION; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MAST CELL; MONOCYTE; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; TH2 CELL; ANIMAL; CELL DIFFERENTIATION; COMPLEMENT ACTIVATION; HYPERSENSITIVITY; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PROTEIN DEGRADATION; TH1 CELL;

ADAPTIVE IMMUNITY; ANIMALS; CELL DIFFERENTIATION; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; IMMUNOMODULATION; PROTEOLYSIS; TH1 CELLS; TH17 CELLS;

EID: 84992445096     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12473     Document Type: Review

References (179)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
2. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–183.
3. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682–687.
4. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity. 2005;22:415–426.
5. Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013;122:3473–3481.
6. 2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. 2013;126:2903–2913.
7. Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM. Complement-mediated “bystander” damage initiates host NLRP3 inflammasome activation. J Cell Sci. 2016;129:1928–1939.
8. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med. 2012;18:1401–1406.
9. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37:199–207.
10. Liszewski MK, Kolev M, Le Friec G, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39:1143–1157.
11. + T cells. Science. 2016;352:aad1210. doi:10.1126/science.aad1210.
12. Cardone J, Le Friec G, Vantourout P, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol. 2010;11:862–871.
13. Le Friec G, Sheppard D, Whiteman P, et al. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat Immunol. 2012;13:1213–1221.
14. Kohl J, Baelder R, Lewkowich IP, et al. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest. 2006;116:783–796.
15. Lajoie S, Lewkowich IP, Suzuki Y, et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11:928–935.
16. Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol. 2013;14:162–171.
17. + dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol. 2011;12:1194–1201.
18. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276–286.
19. Kohl J. The role of complement in danger sensing and transmission. Immunol Res. 2006;34:157–176.
20. Kolev M, Le Friec G, Kemper C. Complement–tapping into new sites and effector systems. Nat Rev Immunol. 2014;14:811–820.
21. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45–56.
22. Hasegawa K, Tamari M, Shao C, et al. Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet. 2004;115:295–301.
23. Karp CL, Grupe A, Schadt E, et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol. 2000;1:221–226.
24. Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 2000;406:998–1001.
25. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med. 2001;164:1841–1843.
26. Zhao YX, Andoh A, Shimada M, et al. Secretion of complement components of the alternative pathway (C3 and factor B) by the human alveolar type II epithelial cell line A549. Int J Mol Med. 2000;5:415–419.
27. Varsano S, Kaminsky M, Kaiser M, Rashkovsky L. Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax. 2000;55:364–369.
28. Khirwadkar K, Zilow G, Oppermann M, Kabelitz D, Rother K. Interleukin-4 augments production of the third complement component by the alveolar epithelial cell line A549. Int Arch Allergy Immunol. 1993;100:35–41.
29. Acevedo F, Palmberg L, Larsson K. Exposure to organic dust causes activation of human plasma complement factors C3 and B and the synthesis of factor C3 by lung epithelial cells in vitro. Inflammation. 2005;29:39–45.
30. Walters DM, Breysse PN, Schofield B, Wills-Karp M. Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2002;27:413–418.
31. Taube C, Thurman JM, Takeda K, et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci USA. 2006;103:8084–8089.
32. Takeda K, Thurman JM, Tomlinson S, et al. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol. 2012;188:661–667.
33. Wang Y, Miwa T, Ducka-Kokalari B, et al. Properdin contributes to allergic airway inflammation through local C3a generation. J Immunol. 2015;195:1171–1181.
34. Dillard P, Wetsel RA, Drouin SM. Complement C3a regulates Muc5ac expression by airway Clara cells independently of Th2 responses. Am J Respir Crit Care Med. 2007;175:1250–1258.
35. Maruo K, Akaike T, Ono T, Okamoto T, Maeda H. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol. 1997;100:253–260.
36. Huber-Lang M, Younkin EM, Sarma JV, et al. Generation of C5a by phagocytic cells. Am J Pathol. 2002;161:1849–1859.
37. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009;15:410–416.
38. Nathan AT, Peterson EA, Chakir J, Wills-Karp M. Innate immune responses of airway epithelium to house dust mite are mediated through beta-glucan-dependent pathways. J Allergy Clin Immunol. 2009;123:612–618.
39. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457:585–588.
40. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012;18:684–692.
41. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46:2753–2766.
42. Sun L, Guo RF, Gao H, Sarma JV, Zetoune FS, Ward PA. Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J. 2009;23:3808–3818.
43. Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65:500–543.
44. Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 2013;27:855–864.
45. Ames RS, Li Y, Sarau HM, et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem. 1996;271:20231–20234.
46. Drouin SM, Kildsgaard J, Haviland J, et al. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol. 2001;166:2025–2032.
47. Mizutani N, Nabe T, Yoshino S. Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice. J Immunol. 2009;183:4039–4046.
48. Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology. 2012;217:225–234.
49. Gutzmer R, Kother B, Zwirner J, et al. Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a. J Invest Dermatol. 2006;126:2422–2429.
50. Solomkin JS, Jenkins MK, Nelson RD, Chenoweth D, Simmons RL. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery. 1981;90:319–327.
51. Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem. 1989;264:1760–1766.
52. Skokowa J, Ali SR, Felda O, et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol. 2005;174:3041–3050.
53. Dunkelberger J, Zhou L, Miwa T, Song WC. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J Immunol. 2012;188:4032–4042.
54. Karsten CM, Laumonnier Y, Eurich B, et al. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J Immunol. 2015;194:1841–1855.
55. Nakano H, Moran TP, Nakano K, Gerrish KE, Bortner CD, Cook DN. Complement receptor C5aR1/CD88 and dipeptidyl peptidase-4/CD26 define distinct hematopoietic lineages of dendritic cells. J Immunol. 2015;194:3808–3819.
56. + T cells. Immunity. 2008;28:425–435.
57. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. Immunobiology. 2012;217:216–224.
58. Cravedi P, van der Touw W, Heeger PS. Complement regulation of T-cell alloimmunity. Semin Nephrol. 2013;33:565–574.
59. Bamberg CE, Mackay CR, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem. 2010;285:7633–7644.
60. Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. 2008;86:153–160.
61. Okinaga S, Slattery D, Humbles A, et al. C5L2, a nonsignaling C5A binding protein. Biochemistry. 2003;42:9406–9415.
62. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol. 2000;37:407–412.
63. Bautsch W, Hoymann HG, Zhang Q, et al. Cutting edge: guinea pigs with a natural C3a receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol. 2000;165:5401–5405.
64. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol. 2002;169:5926–5933.
65. Zhang X, Lewkowich IP, Kohl G, Clark JR, Wills-Karp M, Kohl J. A protective role for C5a in the development of allergic asthma associated with altered levels of B7-H1 and B7-DC on plasmacytoid dendritic cells. J Immunol. 2009;182:5123–5130.
66. Roy RM, Paes HC, Nanjappa SG, et al. Complement component 3C3 and C3a receptor are required in chitin-dependent allergic sensitization to Aspergillus fumigatus but dispensable in chitin-induced innate allergic inflammation. MBio. 2013;4:pii:e00162-13.
67. Schmudde I, Laumonnier Y, Kohl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol. 2013;25:2–11.
68. Lim H, Kim YU, Drouin SM, et al. Negative regulation of pulmonary Th17 responses by C3a anaphylatoxin during allergic inflammation in mice. PLoS ONE. 2012;7:e52666.
69. Drouin SM, Sinha M, Sfyroera G, Lambris JD, Wetsel RA. A protective role for the fifth complement component (c5) in allergic airway disease. Am J Respir Crit Care Med. 2006;173:852–857.
70. McKinley L, Kim J, Bolgos GL, Siddiqui J, Remick DG. Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice. Respir Res. 2006;7:129.
71. Stiehm M, Bufe A, Peters M. Proteolytic activity in cowshed dust extracts induces C5a release in murine bronchoalveolar lavage fluids which may account for its protective properties in allergic airway inflammation. Thorax. 2013;68:31–38.
72. Staab EB, Sanderson SD, Wells SM, Poole JA. Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma. Int Immunopharmacol. 2014;21:293–300.
73. Zhang X, Schmudde I, Laumonnier Y, et al. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol. 2010;185:6741–6752.
74. Chen NJ, Mirtsos C, Suh D, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007;446:203–207.
75. Abe M, Shibata K, Akatsu H, et al. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol. 2001;167:4651–4660.
76. Baelder R, Fuchs B, Bautsch W, et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol. 2005;174:783–789.
77. Weaver DJ Jr, Reis ES, Pandey MK, et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol. 2010;40:710–721.
78. Li K, Anderson KJ, Peng Q, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood. 2008;112:5084–5094.
79. Raymond M, Rubio M, Fortin G, et al. Selective control of SIRP-alpha-positive airway dendritic cell trafficking through CD47 is critical for the development of T(H)2-mediated allergic inflammation. J Allergy Clin Immunol. 2009;124:1333–1342 e1331.
80. Helft J, Bottcher J, Chakravarty P, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity. 2015;42:1197–1211.
81. Engelke C, Wiese AV, Schmudde I, et al. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma. J Immunol. 2014;193:5387–5401.
82. Schmudde I, Strover HA, Vollbrandt T, et al. C5a receptor signalling in dendritic cells controls the development of maladaptive Th2 and Th17 immunity in experimental allergic asthma. Mucosal Immunol. 2013;6:807–825.
83. Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol. 2009;19:340–354.
84. Simon D, Simon HU, Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy. 2013;68:409–416.
85. Leliefeld PH, Koenderman L, Pillay J. How neutrophils shape adaptive immune responses. Front Immunol. 2015;6:471.
86. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–1235.
87. DiScipio RG, Schraufstatter IU. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int Immunopharmacol. 2007;7:1909–1923.
88. Goetzl EJ, Austen KF. Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis. J Exp Med. 1976;144:1424–1437.
89. Elsner J, Oppermann M, Kapp A. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur J Immunol. 1996;26:1560–1564.
90. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5:788–792.
91. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. 2002;110:1823–1830.
92. Hu R, Chen ZF, Yan J, et al. Complement C5a exacerbates acute lung injury induced through autophagy-mediated alveolar macrophage apoptosis. Cell Death Dis. 2014;5:e1330.
93. + regulatory T cells and promote airway tolerance. J Exp Med. 2013;210:775–788.
94. Bandukwala HS, Clay BS, Tong J, et al. Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med. 2007;204:1875–1889.
95. Dharajiya N, Vaidya SV, Murai H, et al. FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma. PLoS ONE. 2010;5:e9337.
96. Mehlhop PD, van de Rijn M, Goldberg AB, et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA. 1997;94:1344–1349.
97. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94–108.
98. Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268:25–51.
99. Tjota MY, Williams JW, Lu T, et al. IL-33-dependent induction of allergic lung inflammation by FcgammaRIII signaling. J Clin Invest. 2013;123:2287–2297.
100. Karsten CM, Kohl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology. 2012;217:1067–1079.
101. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
102. Koide N, Nose M, Muramatsu T. Recognition of IgG by Fc receptor and complement: effects of glycosidase digestion. Biochem Biophys Res Commun. 1977;75:838–844.
103. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA. 1983;80:6632–6636.
104. Tsuchiya N, Endo T, Matsuta K, et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol. 1989;16:285–290.
105. Williams RC Jr, Osterland CK, Margherita S, Tokuda S, Messner RP. Studies of biologic and serologic activities of rabbit-IgG antibody depleted of carbohydrate residues. J Immunol. 1973;111:1690–1698.
106. Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 1994;180:1087–1096.
107. Silverton EW, Navia MA, Davies DR. Three-dimensional structure of an intact human immunoglobulin. Proc Natl Acad Sci USA. 1977;74:5140–5144.
108. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1:237–243.
109. Oefner CM, Winkler A, Hess C, et al. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol. 2012;129:1647–1655 e1613.
110. Wang J, Balog CI, Stavenhagen K, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics. 2011;10:M110 004655.
111. Shan M, Gentile M, Yeiser JR, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 2013;342:447–453.
112. Hirabayashi J, Kasai K. The family of metazoan metal-independent beta-galactosidebinding lectins: structure, function and molecular evolution. Glycobiology. 1993;3:297–304.
113. Boscher C, Dennis JW, Nabi IR. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol. 2011;23:383–392.
114. Radicioni G, Cao R, Carpenter J, et al. The innate immune properties of airway mucosal surfaces are regulated by dynamic interactions between mucins and interacting proteins: the mucin interactome. Mucosal Immunol. 2016. doi:1038/mi.2016.27 [Epub ahead of print].
115. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature. 2014;505:412–416.
116. Fang C, Zhang X, Miwa T, Song WC. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood. 2009;114:1005–1015.
117. Schmitz V, Almeida LN, Svensjo E, Monteiro AC, Kohl J, Scharfstein J. C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection. J Immunol. 2014;193:3613–3623.
118. Kulkarni U, Karsten CM, Kohler T, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016;137:1487–1497 e1486.
119. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 2006;18:265–270.
120. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944–950.
121. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221–241.
122. Vicioso MA, Garaud JJ, Reglier-Poupet H, Lebeaut A, Gougerot-Pocidalo MA, Chollet-Martin S. Moderate inhibitory effect of interleukin-10 on human neutrophil and monocyte chemotaxis in vitro. Eur Cytokine Netw. 1998;9:247–253.
123. Nakagome K, Matsushita S, Nagata M. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol. 2012;158(Suppl 1):96–102.
124. + regulatory T cells is interleukin 10 dependent. J Exp Med. 2005;202:1539–1547.
125. van Lookeren Campagne M, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell Microbiol. 2007;9:2095–2102.
126. Nelson RA. The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science (New York, NY). 1953;118:733–737.
127. Nelson RA. The immune-adherence phenomenon; a hypothetical role of erythrocytes in defence against bacteria and viruses. Proc R Soc Med. 1956;49:55–58.
128. Fearon DT. The human C3b receptor. Springer Semin Immunopathol. 1983;6:159–172.
129. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med. 1987;165:1095–1112.
130. Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med. 2000;192:1797–1808.
131. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity. 1997;7:345–355.
132. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med. 1982;155:1427–1438.
133. Minota S, Terai C, Nojima Y, et al. Low C3b receptor reactivity on erythrocytes from patients with systemic lupus erythematosus detected by immune adherence hemagglutination and radioimmunoassays with monoclonal antibody. Arthritis Rheum. 1984;27:1329–1335.
134. Macedo ACL, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol. 2016;7:55.
135. Hebert LA, Birmingham DJ, Shen XP, Cosio FG, Fryczkowski A. Rate of antigen entry into the circulation in experimental versus naturally occurring immune complex glomerulonephritis. J Am Soc Nephrol. 1994;5:S70–75.
136. Emlen W, Burdick G, Carl V, Lachmann PJ. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells. J Immunol (Baltimore, Md: 1950). 1989;142:4366–4371.
137. Nardin A, Schlimgen R, Holers VM, Taylor RP. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model. Eur J Immunol. 1999;29:1581–1586.
138. Craig ML, Waitumbi JN, Taylor RP. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1. J Immunol (Baltimore, Md: 1950). 2005;174:3059–3066.
139. Chen W, Logar CM, Shen XP, Birmingham DJ. The chimpanzee and cynomolgus monkey erythrocyte immune adherence receptors are encoded by CR1-like genes. Immunogenetics. 2000;52:46–52.
140. Birmingham DJ, Hebert LA, Shen XP, Higgins P, Yeh CG, Creasey AA. Effects of immune complex formation and complement activation on circulating platelets in the primate. Clinical Immunology (Orlando, Fla). 1999;91:99–105.
141. Yin W, Cui J, Jiang J, et al. The immune adherence receptor CR1-like existed on porcine erythrocytes membrane. Sci Rep. 2015;5:13290.
142. Alexander JJ, Hack BK, Cunningham PN, Quigg RJ. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem. 2001;276:32129–32135.
143. Bergmeier W, Piffath CL, Cheng G, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res. 2004;95:677–683.
144. Paccaud JP, Carpentier JL, Schifferli JA. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol (Baltimore, Md: 1950). 1988;141:3889–3894.
145. Kasirer-Friede A, Ware J, Leng L, Marchese P, Ruggeri ZM, Shattil SJ. Lateral clustering of platelet GP Ib-IX complexes leads to up-regulation of the adhesive function of integrin alpha IIbbeta 3. J Biol Chem. 2002;277:11949–11956.
146. Waxman FJ, Hebert LA, Cornacoff JB, et al. Complement depletion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest. 1984;74:1329–1340.
147. Davies KA, Peters AM, Beynon HL, Walport MJ. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest. 1992;90:2075–2083.
148. Lindorfer MA, Nardin A, Foley PL, et al. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol (Baltimore, Md: 1950). 2001;167:2240–2249.
149. Broadley SP, Plaumann A, Coletti R, et al. Dual-track clearance of bacteremia balances rapid restoration of blood sterility with adaptive immune induction. Cell Host Microbe. 2016;20:36–48.
150. Morris DH, Bullock FD. The importance of the spleen in resistance to infection. Ann Surg. 1919;70:513–521.
151. Parker JT, Franke E. The fate of typhoid bacilli injected intravenously into normal and typhoid immune rabbits. The Journal of Medical Research. 1919;39:301–309.
152. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ. 1972;46:845–852.
153. Gordon S, Pluddemann A, Mukhopadhyay S. Sinusoidal immunity: macrophages at the lymphohematopoietic interface. Cold Spring Harbor Perspectives in Biology. 2015;7:a016378.
154. Mebius RE, Nolte MA, Kraal G. Development and function of the splenic marginal zone. Crit Rev Immunol. 2004;24:449–464.
155. Ellison EC, Fabri PJ. Complications of splenectomy. Etiology, prevention, and management. The Surgical Clinics of North America. 1983;63:1313–1330.
156. Yrlid U, Wick MJ. Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter. J Immunol (Baltimore, Md: 1950). 2002;169:108–116.
157. + dendritic cells during infection with intracellular pathogens. Immunol Lett. 2007;114:66–72.
158. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10:753–766.
159. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14:996–1006.
160. Wardlaw AC, Howard JG. A comparative survey of the phagocytosis of different species of bacteria by Kupffer cells; perfusion studies with the isolated rat liver. Br J Exp Pathol. 1959;40:113–117.
161. Gregory SH, Sagnimeni AJ, Wing EJ. Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol (Baltimore, Md: 1950). 1996;157:2514–2520.
162. Ebe Y, Hasegawa G, Takatsuka H, et al. The role of Kupffer cells and regulation of neutrophil migration into the liver by macrophage inflammatory protein-2 in primary listeriosis in mice. Pathol Int. 1999;49:519–532.
163. Samsom JN, Annema A, Groeneveld PH, van Rooijen N, Langermans JA, van Furth R. Elimination of resident macrophages from the livers and spleens of immune mice impairs acquired resistance against a secondary Listeria monocytogenes infection. Infect Immun. 1997;65:986–993.
164. Pinto AJ, Stewart D, van Rooijen N, Morahan PS. Selective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene diphosphonate: effects on antimicrobial resistance. J Leukoc Biol. 1991;49:579–586.
165. Kurahashi K, Sawa T, Ota M, et al. Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol. 2009;296:L198–209.
166. Hirakata Y, Tomono K, Tateda K, et al. Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia. Infect Immun. 1991;59:289–294.
167. Wong CHY, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with bloodborne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14:785–792.
168. Nakamura Y, Aramaki Y, Kakiuchi T. A mouse model for postoperative fatal enteritis due to Staphylococcus infection. J Surg Res. 2001;96:35–43.
169. Lee W-Y, Moriarty TJ, Wong CHY, et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol. 2010;11:295–302.
170. Cote CK, Rea KM, Norris SL, van Rooijen N, Welkos SL. The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with Bacillus anthracis spores. Microb Pathog. 2004;37:169–175.
171. Cote CK, van Rooijen N, Welkos SL. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun. 2006;74:469–480.
172. Qian Q, Jutila MA, van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol (Baltimore, Md: 1950). 1994;152:5000–5008.
173. Schwocho LR, Moon RJ. Clearance and killing of Candida albicans in the perfused mouse liver. Mycopathologia. 1981;76:175–183.
174. Nieuwenhuijzen GA, Haskel Y, Lu Q, et al. Macrophage elimination increases bacterial translocation and gut-origin septicemia but attenuates symptoms and mortality rate in a model of systemic inflammation. Ann Surg. 1993;218:791–799.
175. Balmer ML, Slack E, Gottardi AD, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014;6:237ra266.
176. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12.
177. Gustot T, Durand F, Lebrec D, Vincent J-L, Moreau R. Severe sepsis in cirrhosis. Hepatology (Baltimore, MD). 2009;50:2022–2033.
178. Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceaseddonor liver transplant. N Engl J Med. 2008;358:369–374.
179. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12:201–213.